At CD BioSciences, our Companion Diagnostic (CDx) Development services bridge targeted biopharmaceutical therapies with precision diagnostics. We partner with pharmaceutical sponsors to codevelop custom CDx assays that identify patients most likely to benefit from specific targeted treatments, monitor therapeutic response, guide dosage adjustments, and inform treatment continuation or discontinuation decisions.

By aligning diagnostic development with therapeutic clinical timelines, our end-to-end CDx platform significantly enhances clinical trial success rates, improves patient safety profiles, and accelerates global regulatory approval—delivering true precision medicine to the market.